CD274 and small cell lung carcinoma: Interestingly, the 5-year OS data of IMpower133 and the IMbrella A extension study revealed that a small, but clinically significant proportion of patients with ES-SCLC can derive long-term benefits from PD-L1 blockage, with 12% of patients still alive at 5 years [14].